Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
| Autor: | Gabriel Castano, Mark Feldman, Arvin Parvathaneni, John King, Pradeep Kumar Mada, Maureen Moore, Mohammed J. Alam, Sharon Adley, Bing Chen, Matthew E Malus, Michinari Hieda |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Hepatology Article Subject business.industry RC799-869 Hepatitis C Diseases of the digestive system. Gastroenterology medicine.disease Treatment and control groups 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Diabetes mellitus Internal medicine Concomitant Ambulatory medicine 030211 gastroenterology & hepatology In patient Viral hepatitis business Glycemic Research Article |
| Zdroj: | International Journal of Hepatology International Journal of Hepatology, Vol 2020 (2020) |
| ISSN: | 2090-3456 2090-3448 |
| Popis: | Aim. To assess the effect of treating chronic hepatitis C virus (HCV) infection with direct acting antiviral drugs (DAAs) on glycemic control in patients with concomitant diabetes mellitus (DM). Methods. We performed a retrospective case-control study in a viral hepatitis ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014 to 12/31/2017. All the clinic patient ages 18 years and above with treatment-naïve/biopsy-proven chronic hepatitis C and DM (hemoglobin A1C level≥6.5%) who were eligible for treatment were included in the study. Of 118 such patients, 59 were treated with oral DAAs for 8-12 weeks with the goal of achieving a sustained virologic response (SVR). A control group of 59 patients did not receive treatment for their hepatitis C and was followed in the clinic. Patients in the control group did not receive treatment either due to insurance issues or refusal of hepatitis C treatment. Results. Fifty-five of the 59 patients treated with DAAs (93%) achieved a SVR. Six months after treatment completion, their mean±SEM HbA1C level had decreased by 1.1±0.03% (P<0.0001). Four of the 59 patients treated with DAAs did not achieve a SVR. Their mean HbA1C 6 months after treatment completion had increased by 0.8±0.2%. Furthermore, there was no improvement in HbA1C levels over time in the untreated group (mean HbA1C increase, 0.2±0.05%; P<0.0001 vs. the treatment group, which had a mean HbA1C decrease of 0.9±0.2%). Conclusion. This controlled study demonstrated that treatment of chronic hepatitis C with DAAs results in statistically significant and meaningful reductions in hemoglobin A1C levels in patients with coexisting diabetic mellitus if a SVR is achieved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text